Literature DB >> 21369775

Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia?

Satoshi Kawasaki1, Nobuki Aoki, Hiroshi Kikuchi, Hitoshi Nakayama, Noriko Saito, Hisaki Shimada, Shigeru Miyazaki, Shinji Sakai, Masashi Suzuki, Ichiei Narita.   

Abstract

Although hemodialysis-associated pneumonia (HDAP) was included among the healthcare-associated pneumonias (HCAP) in the 2005 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guideline, little information relevant to clinical epidemiology, especially microbiological characteristics, is available. This study aimed to reveal microbiological characteristics and clinical outcomes of HDAP and to assess whether HDAP should be included in the HCAP category. We retrospectively analyzed 69 HDAP patients [42 with moderate and 27 with severe disease based on A-DROP (age, dehydration, respiratory failure, orientation disturbance, and low blood pressure)] in whom sputum cultures were performed at our hospital between 2007 and 2009. The most common pathogens were Staphylococcus aureus (37.7%), which were composed of methicillin-resistant S. aureus (MRSA) (27.5%) and methicillin-sensitive S. aureus (MSSA) (10.1%), followed by Streptococcus pneumoniae (10.1%), Klebsiella pneumoniae (8.7%), Haemophilus influenzae (7.2%), and Moraxella catarrhalis (5.8%). This distribution mostly resembled the microbiological characteristics of HCAP reported previously, except that the frequency of multi-drug-resistant (MDR) gram negatives such as Pseudomonas aeruginosa (2.9%) was clearly lower and that of MRSA was higher. There were no significant differences in microbiological findings, including the incidence of MDR pathogens, between the two severity groups. Despite most cases (82.6%) receiving only monotherapy, the prognosis (30-day survival and in-hospital mortality rates were 88.4% and, 17.4%, respectively) was similar to the past HCAP reports, but there were no significant correlations between prognosis and presence of MDR pathogens (30-day mortality rates 18.2% in MDR positive vs. 8.5% in MDR negative; p = 0.242). Assessment for not only MDR pathogens, but also severity of illness by the A-DROP system made it possible to conduct stratification based on prognosis. Our results suggest that HDAP should be included in the HCAP category, while understanding that there are some differences.

Entities:  

Mesh:

Year:  2011        PMID: 21369775     DOI: 10.1007/s10156-011-0228-z

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

Review 1.  Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis.

Authors:  Anthony X Troitino; Jahan Porhomayon; Ali A El-Solh
Journal:  Lung       Date:  2013-04-10       Impact factor: 2.584

2.  Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia.

Authors:  Ping-Huai Wang; Hao-Chien Wang
Journal:  BMC Infect Dis       Date:  2016-08-08       Impact factor: 3.090

3.  Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia.

Authors:  Jae-Uk Song; Hye Kyeong Park; Hyung Koo Kang; Jonghoo Lee
Journal:  BMC Infect Dis       Date:  2017-10-12       Impact factor: 3.090

4.  A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.

Authors:  Issei Tokimatsu; Katsumi Shigemura; Tomohiro Kotaki; Hiroki Yoshikawa; Fukashi Yamamichi; Tadashi Tomo; Soichi Arakawa; Masato Fujisawa; Jun-Ichi Kadota
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

5.  Epidemiology of healthcare-associated infections among patients from a hemodialysis unit in southeastern Brazil.

Authors:  Silvia Eduara Kennerly de Albuquerque; Ricardo de Souza Cavalcante; Daniela Ponce; Carlos Magno Castelo Branco Fortaleza
Journal:  Braz J Infect Dis       Date:  2013-11-22       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.